Pancreatic Cancer Pain Clinical Trial
Official title:
Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain
- Hypothesis:
- Direct CGN enhances neurolytic drug delivery into celiac ganglia and increases the
efficacy of neurolysis and subsequent pain control and survival in patients with
pancreatic carcinoma.
- Rationale:
- Standard CPN leads to inaccurate delivery of the injectate with rapid dispersal
thereby only briefly remaining in contact with neural structures and limiting the
degree of neurolysis. Poor targeting and delivery of a neurolytic agent may result
in diminished neurolysis and decrease efficacy.
n/a